Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 118.53M | 42.28M | 0.00 | 458.00K | 40.00M | 0.00 |
Gross Profit | 112.28M | 39.70M | -679.62K | 112.00K | 40.00M | -627.85K |
EBITDA | -176.07M | -142.19M | -52.47M | -67.29M | -42.19M | -47.81M |
Net Income | -164.02M | -173.42M | -54.37M | -68.70M | -55.57M | -65.15M |
Balance Sheet | ||||||
Total Assets | 525.94M | 474.24M | 308.12M | 259.47M | 186.59M | 204.21M |
Cash, Cash Equivalents and Short-Term Investments | 401.42M | 399.76M | 271.77M | 227.83M | 148.38M | 187.99M |
Total Debt | 2.13M | 122.70M | 51.33M | 10.65M | 5.81M | 5.95M |
Total Liabilities | 299.34M | 269.68M | 58.84M | 29.00M | 38.58M | 19.35M |
Stockholders Equity | 226.59M | 204.56M | 249.28M | 230.47M | 148.00M | 184.85M |
Cash Flow | ||||||
Free Cash Flow | -120.37M | -122.78M | -50.22M | -59.89M | -33.27M | -45.16M |
Operating Cash Flow | -119.80M | -122.20M | -50.22M | -59.86M | -33.25M | -45.08M |
Investing Cash Flow | -1.10M | -580.00K | 0.00 | -29.00K | -12.00K | 9.71M |
Financing Cash Flow | 267.04M | 250.78M | 92.87M | 140.82M | -6.12M | 192.34M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $4.02B | 34.04 | 13.90% | ― | 247.53% | 118.34% | |
77 Outperform | $4.78B | 13.81 | 25.71% | ― | -12.31% | -17.53% | |
68 Neutral | $7.67B | ― | -72.73% | ― | ― | -157.53% | |
57 Neutral | $6.22B | ― | -4584.47% | ― | 28.20% | 13.87% | |
46 Neutral | C$194.85M | -4.28 | -8.56% | 2.84% | 13.52% | -1.74% | |
45 Neutral | $4.02B | ― | 435.49% | ― | 412.21% | 1.75% | |
43 Neutral | $5.78B | ― | -35.69% | ― | ― | -81.09% |
On March 27, 2025, Verona Pharma announced an amendment to its credit agreement with Oaktree, increasing the Tranche C Term Loans from $75 million to $125 million and reducing the interest rate from 11% to 9.7%, with a further reduction to 9.35% upon meeting sales milestones. The amendment also includes a $75 million basket for a future working capital facility. On March 28, 2025, Verona Pharma repurchased its $100 million RIPSA obligation with reduced fees and increased its term loan facility to $450 million with improved terms. This strategic move enhances Verona Pharma’s financial flexibility and supports the continued growth of its COPD treatment, Ohtuvayre, while maintaining access to an additional $200 million under the term loan facility.